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Tuberculosis is a leading cause of death in mankind due to infectious agents, and
Mycobacterium tuberculosis (Mtb) infects and survives in macrophages (MФs). Although
MФs are a major niche, myeloid-derived suppressor cells (MDSCs) are an alternative site
for pathogen persistence. Both MФs and MDSCs express varying levels of leukocyte
immunoglobulin-like receptor B (LILRB), which regulate the myeloid cell suppressive
function. Herein, we demonstrate that antagonism of LILRB2 by a monoclonal antibody
(mab) induced a switch of human MDSCs towards an M1-macrophage phenotype,
increasing the killing of intracellular Mtb. Mab-mediated antagonism of LILRB2 alone and
its combination with a pharmacological blockade of SHP1/2 phosphatase increased
proinﬂammatory cytokine responses and phosphorylation of ERK1/2, p38 MAPK, and
NF-kB in Mtb-infected MDSCs. LILRB2 antagonism also upregulated anti-mycobacterial
iNOS gene expression and an increase in both nitric oxide and reactive oxygen species
synthesis. Because genes associated with the anti-mycobacterial function of M1-MФs
were enhanced in MDSCs following mab treatment, we propose that LILRB2 antagonism
reprograms MDSCs from an immunosuppressive state towards a pro-inﬂammatory
phenotype that kills Mtb. LILRB2 is therefore a novel therapeutic target for eradicating
Mtb in MDSCs.
Keywords: tuberculosis, MDSC (myeloid-derived suppressor cell), LILRB, monoclonal antibody, Mycobacterium
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GRAPHICAL ABSTRACT | LILRB2 antagonism enhances killing of Mycobacterium tuberculosis in Myeloid derived Suppressor Cells (MDSCs).

and late stages of TB, a variety of suppressor cells including
MDSCs and T and B regulatory cells (Tregs and Bregs) may
emerge and aggravate the disease severity (9). We therefore sought
to determine whether the suppressive function of MDSCs can be
abrogated. We noted that MDSCs are either derived from
monocytic (M-MDSCs) or neutrophilic (N-MDSCs) lineage
(11, 12). The molecular mechanisms through which these
phenotypes occur and their immune regulation during
tuberculosis remain unclear (5, 13).
We recently described that the human leukocyte
immunoglobulin-like receptors (LILRBs) and its mouse
counterpart, paired immunoglobulin-like receptor B (PIR-B),
are critical cell surface receptors that regulate the functional
phenotype of MDSCs and MФs (14, 15). PIR-B is a key
regulator for maintaining the M2 phenotype of tumorinﬁltrating MDSCs, and we demonstrated for the ﬁrst time that
blockade of LILRB2 induces differentiation MDSCs into the M1
type of macrophages, altering the tumor microenvironment
towards anticancer responses (16). In this direction, we
developed agonist and antagonist antibodies against human
LILRB2, which have the potential to enter clinical applications.
Because TB requires prolonged chemotherapy and MDR-TB
poses a challenge to treat, we hypothesized that LILRB2
modulation can be used to target Mtb containing MDSCs for
controlling TB. Herein, we demonstrate that LILRB2-speciﬁc mab
activation of MDSCs skews them into an M1-phenotype
enhancing their ability to kill Mtb.

INTRODUCTION
Mycobacterium tuberculosis (Mtb) that causes tuberculosis (TB)
kills about 1 million people each year. Macrophages (MФs) are
the major niche for either replication or persistence of Mtb and
require IFN-g-mediated activation to kill Mtb through nitric
oxide (NO), reactive oxygen species (ROS), and autophagy or
phagosome–lysosome (PL) fusion mechanisms. MФs are
heterogeneous in nature with M1-MФ and M2-MФ major
subsets (1). We recently showed that Mtb infection induced
striking transcriptomic changes in both rested and IFN-g
differentiated M1-MФs; the latter killed Mtb using NO and
autophagy-dependent mechanisms. In contrast, IL-4programmed M2-MФs allowed the growth of Mtb due to
defects in these antimycobacterial mechanisms (2).
Emerging evidence suggests a critical role of myeloid-derived
suppressor cells (MDSCs) in promoting immunosuppression in
cancers, and they are a major target for immunotherapy of cancer
(3). Curiously, MDSCs also arise during the pathogenesis of
tuberculosis; they are found in the blood and lung granulomas
of TB patients and thought to exacerbate disease severity by
secreting anti-inﬂammatory cytokines besides a direct
suppressive interaction with other immune cells (4–8). Although
chronic mycobacterial infection triggers an expansion of MDSCs,
less is known about MDSCs as an Mtb reservoir and strategies to
eliminate the pathogen (9, 10). Whereas anti-TB immunity is
regulated by the Th1/TH17/IFN-g-dependent axis, during early
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Fluorochrome-conjugated antibodies, FITC anti-human CD14
(Biolegend, #367115), PE anti-human CD15 (Biolegend,
#301905), PE-Cy7 anti-human HLADR (Biolegend, #307615),
APC anti-human CD33 (Biolegend, #366605), and Fixable
Viability Stain 510 (BD Biosciences, #564406). Cells were
analyzed on the Fortessa ﬂow cytometer 202 (Beckton
Dickinson), and the data were processed using FlowJo v10
software (Tree Star, Inc.).

MATERIALS AND METHODS
Statistics
Graphpad Prism was used to analyze data and obtain p-values.
All experiments contained biological triplicates and were done at
least two independent times.

Study Approval
The procedures of sample collection and analyses were approved
by HSC-SPH-12-0037.

Infection and Colony-Forming Unit Counts
of M. tuberculosis in MDSCs

Blood Samples

MDSCs were plated at 106 per well in 24-well adherent plates. Mtb
H37Rv (ATCC 27294) was grown in Middlebrook 7H9 broth
supplemented with 0.05% (v/v) Tween 80 and Middlebrook
AODC enrichment (Difco, Becton Dickinson) to mid-log phase
(OD 600 nm 0.6± 0.8). Early log phase cultures of Mtb suspensions
were sonicated at 4 W for 60 s using a sonicator to prepare a
uniform single-cell suspension and then MDSCs were infected with
Mtb at a MOI of 1. After 4 h of infection, cells were washed and
added with LILRB-2 mab (mab-B2) or its IgG control antibody for
18 h at 1 µg/ml per 10*6 MDSCs for 7 days. Mtb counts were
expressed as log10 CFU counts averaged for triplicate wells of
MDSCs per group or combination and experiments were repeated
two times. p-value for differences in CFUs was determined using 1way ANOVA using Tukey’s posttest.

Samples from healthy donors and TB patients were obtained
following approved IRB procedures. Within TB patient and
healthy controls, the samples were randomized for age, sex, and
other demographics for unbiased analysis (Supplementary
Table 1). From 10 ml of blood, 1 ml was subjected to RBC lysis,
centrifuged at 400g for 5 min. PBS washed cells were stained with
100 µl of viability dye for 5 min. Cells were then washed with PBS +
1% FBS and blocked with 50 µl of PBS + 1% FBS containing human
Fc block for 10 min, followed by 50–100 µl of antibodies
(Supplementary Table 1) against various immune cells using our
CyTOF (cytometry by time of ﬂight or mass cytometry; HMRI)
core. Cells were mixed and incubated for 30 min, and washed four
times with PBS + 1% FBS followed by overnight ﬁxation. From the
remaining 9 ml of blood, PBMCs were also isolated using
Ficoll®Paque Plus (GE Healthcare #17-1440-02) and were stained
with antibodies as above and used for CyTOF analysis.

Effect of siRNA Blockade of
Nitric Oxide and Autophagy on
The Growth of Mtb in MDSCs

Isolation of MDSCs From Peripheral
Blood Monocytes

MDSCs were subjected to siRNA knockdown for autophagy using
manufacturer’s instructions (18). The kits for human siRNAs
(mixture of duplexes) were purchased from Origene technologies
(Beclin-1 siRNA including scrambled controls: SR322490; iNOS
siRNA: SR303202). MDSCs were treated with siRNA and the
scrambled control, washed, rested, and added with Mtb (H37Rv)
for 4 h of infection (MOI of 1). Cells were washed and added with
mab-LILRB2/3 (1 µg/ml each) or isotype (1 µg/ml) and incubated as
required. Mab was combined with inhibitors (1 µg/ml each) as
needed: SHP1 inhibitor (IACS-13909; #HY-137092/CS-0136474)
and SHP2 inhibitor (TPI-1 #HY-100463/CS-6450) were purchased
from MCE Med Chem Express. At time points, cells were lysed in
0.05% SDS-PBS buffer and 10-fold dilutions were plated on 7H11
agar plates for CFU counts, which were read after 21 days of
incubation. To assess the effects of NO or ROS on Mtb growth in
MDSCs, replicate cultures of mab-treated or untreated MDSCs were
incubated with diamino-ﬂuorescein diacetate (DAN) ﬂuorescent
probe (1 µM) followed by ﬂuorometry using Ascent Fluoroscan
and relative light units (RLUs) plotted for triplicate wells per
treatment group (19). Whole-cell ROS was similarly detected using
ﬂuorometry and dihydro-dichloro-ﬂuorescein diacetate (1 µM) using
live cells as described (20).

MDSCs were isolated as described previously (17). Brieﬂy,
PBMCs from the buffy coat of healthy donors were isolated
using Ficoll®Paque Plus (GE Healthcare #17-1440-02), which
resulted in a yield of about 200 million PBMCs. PBMCs were
then subjected to CD14+ cell fractionation using an EasySep
Human CD14+ positive selection kit (Stem cells; #17858) as per
the manufacturer’s instructions. PBMCs from one buffy coat unit
yielded about 80 million CD14+ cells. The CD14+ cells were
cultured for 6 days in IMDM medium supplemented with 10%
fetal bovine serum in the presence of GM-CSF (10 ng/ml) in
combination with IL-6 (10 ng/ml) to induce their proliferation
into Monocytic-MDSCs. M-MDSCs were then puriﬁed from
CD14+ cells using the EasySep Human CD33 positive selection
kit (Stem cells; #17876) as per the manufacturer’s instructions.
The purity of M-MDSCs (CD15-CD14+CD33+HLADR-) was
found to be >90% by ﬂow cytometry (Supplementary Figure 1).
The total yield for M-MDSCs was in the range of 16–20 million
cells per donor from one unit of buffy coat. To test whether
MDSCs naturally occurring in blood show bactericidal function
after mab activation, for some experiments (Figure 4), CD33+
MDSCs were puriﬁed using FACsorting of PBMCs from
healthy donors.

Flow Cytometry

Immunoﬂuorescence Colocalization Assay
for LC3 Labeling

Flow cytometric analysis was done to assess the purity of M-MDSCs
(henceforth referred to as MDSCs). Cells were stained with

Naive MDSCs were infected using gfp-expressing Mtb (MOI of
1) for 4 h, washed and treated using either mab-B2 or isotype,
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#SAB5600204) was used at 1:50 dilution. The antibodies for iNOS
(Abclonal, #A0312) and STAT1 (#14994T), p-STAT1 (#9167S),
ERK1/2 (#4695T), p-ERK1/2 (#4370 T), p38 MAPK (# 8690T), pp38 MAPK (#4511T), NF-kB (#8242T), and p-NF-kB (#3033T)
were purchased from Cell Signaling Technology. Data were
analyzed with the Compass software (version 2.6.7). The area
under the curve (AUC), which represents the signal intensity of
the chemiluminescent reaction, was analyzed for all the antibodies
and b-actin. Values given for protein expression were normalized to
b-actin. Quantitation of protein levels (area under each peak;
arbitrary units [A.U.]) were performed using the Compass
software (version 2.6.7).

and incubated at 18 h. Post infection, the cells were washed,
plated onto coverslips, ﬁxed in 3.7% paraformaldehyde, and
permeabilized using Tween 80-digitonin-BSA buffer as
described before (18). A speciﬁc mab to LC3 (Cell Signaling
#3868) was used to stain gfpMtb phagosomes followed by Alexa
ﬂuor 555 conjugates. Confocal images were acquired using an
N90 Nikon microscope equipped with a Metaview RT
deconvolution software. Colocalization was determined by
scoring gfpMtb phagosomes of 25 MDSCs in triplicate
chambers per treatment group (18, 21).

qPCR Analysis of CD80, CD206, GBP2,
IRF3, IRF5, and IRF7

Western Blot analysis

Total RNA was extracted from control or treated MDSCs using
the RNAeasy mini kit (Qiagen, Germany). RNA concentration
and purity ratios (OD260/280, OD260/230) were measured
using the NanoDrop ND-1000 spectrophotometer (Thermo
Fisher Scientiﬁc, USA). cDNA synthesis was performed on a
CFX96 Real-Time PCR System (Biorad, USA) using the 2X
OneStep qRT-PCR Mastermix Kit (Applied Biosystems, USA)
according to the manufacturer’s instruction. Quantitative PCR
(qPCR) was performed using SYBR green probe and gene speciﬁc
primers [CD80-5’->3’: CTCTTGGTGCTGGCTGGTCTTT
Forward primer; 5’->3’: GCCAGTAGATGCGAGTTTGTGC
Reverse primer; CD206-5’->3’: AGCCAACACCAGC
TCCTCAAGA Forward primer; 5’->3’: CAAAACGCTCGCGCA
TTGTCCA Reverse primer; GBP2-5’->3’: AGCCAACA
CCAGCTCCTCAAGA Forward primer; 5’->3’: CAAAACGCT
CGCGCATTGTCCA Reverse primer; IRF3-5’->3’:
TCGTGATGGTCAAGGTTGT Forward primer; 5’->3’: AGGTC
CACAGTATTCTCCAG Reverse primer; IRF5-5’->3’: ATG
CTGCCTCTGACCGA Forward primer; 5’->3’: GCC
GAAGAGTTCCACCTG Reverse primer; IRF7-5’->3’: GAG
CCCTTACCTCCCCTGTTAT Forward primer; 5’->3’: CCACT
GCAGCCCCTCATAG Reverse primer]. Threshold cycle
numbers were transformed to DDCt values, and the results were
expressed relative to the reference gene, b-actin, and GAPDH. Gene
expression data were performed using GraphPad Prism ver. 6.0
suite (GraphPad Software). Student’s t-test was used for means
comparison between both uninfected and Mtb-infected MDSCs.
Signiﬁcance was set at the 0.05 level.

For the analysis of LC3B protein, a traditional Western blot was
used as the protein was of small molecular weight. Protein
concentrations were determined using the Bradford Assay
Reagent (Thermo Scientiﬁc: #23238) and 25 µg of total protein
was loaded per well of 4%–20% Mini-Protean TGX gels (Bio-Rad
#4561095) and transferred to nitrocellulose membranes (TransBlot Turbo Transfer pack, Bio-Rad #1704158) using the Bio-Rad
trans-blot turbo transfer system. Antibody against LC3B was used
at a dilution of 1:500 (LC3B Antibody; Novus Biologicals:
#NB100-2220SS). Secondary antibody was added (1:1,000 Antirabbit IgG, HRP-linked Antibody, Cell Signaling #7074s), and the
membranes were then developed using an ECL kit. Densitometry
analysis was done using ImageJ software and LC3 band density
was normalized relative to GAPDH/b-actin (Anti-GAPDH
antibody, Rabbit monoclonal, Sigma-Aldrich #SAB5600208)
or b-actin (Anti-b Actin antibody, Rabbit monoclonal,
Sigma-Aldrich #SAB5600204).

RESULTS
Distribution of Monocytic and Neutrophilic
Myeloid-Derived Suppressor Cells in
PBMCs and Whole Blood of Tuberculosis
Patients and Healthy Donors
During natural infection, Mtb are inhaled and phagocytized by
alveolar MФs. They inﬁltrate into the lung parenchyma and secrete
chemokines to recruit interstitial and blood-deirved monocyteMФs, neutrophils, dendritic cells, and various subsets of T cells to
form an organzied structure called granuloma (22). TB granulomas
contain a central core of Mtb-infected macrophages surrounded by
macrophages, T cells, DCs, and PMNs. Interestingly, MDSCs also
occur in and around tuberculosis granulomas and in the peripheral
blood of TB patients (10). To determine their frequency in
circulation, both PBMCs puriﬁed on Ficoll and whole blood RBC
lysis preparations, from tuberculosis patients (n = 5) and heathy
donors (n = 5), were analyzed using CyTOF. Figure 1 illustrates that
neutrophilic/granulocytic-type N-MDSCs were higher among
PBMCs of TB patients and there was a marked reduction in the
activation of CD8+T cells compared to CD4 T cells. Although MMDSCs were lesser in PBMCs, herein, we pursued their analysis of
because of their potential role during TB. CyTOF analysis was done

Wes-Simple Capillary Electrophoresis
MDSCs were collected and centrifuged for 5 min at 400g and lysed
by using RIPA buffer in the presence of protease inhibitors. For the
analysis of proteins, the quantitative Wes capillary immunoassay
was used, in which the lysates were separated and detected using
Wes separation capillary cartridge 12–230 kDa along with the Wes
Anti-Rabbit Detection Module (Simple Western system and
Compass Software, Protein Simple). (Supplementary Figure 2) In
brief, glass microcapillaries were loaded with stacking and
separation matrices followed by sample loading. During capillary
electrophoresis, proteins were separated by size and then
immobilized to the capillary wall. Samples were loaded at 1 mg/
ml dilution and the primary rabbit antibody was used at a
dilution of 1:50 and b-actin (Rabbit monoclonal, Sigma-Aldrich
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A

B

FIGURE 1 | Distribution of monocyte and neutrophil-derived myeloid-derived suppressor cells (MDSCs) in the blood of healthy donors and tuberculosis patients.
Blood samples from either healthy donors (n = 5) or TB patients (n = 5) were analyzed using CyTOF (mass cytometry) for immune cell populations. N-MDSCs are
increased in TB patients who also show a reduced activation of CD8 T cells (*p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.01, two-tailed t-test). Individual CyTOF
proﬁles, biomarkers, and sample data are shown in Supplementary Table 1 and Supplementary Figure 3.

infected for 4 h, we sought to determine if there are differences in
the uptake of Mtb after a 4-h infection. Microscopic counting of
Mtb within MDSCs using acid fast mycobacterial stains did not
show a signiﬁcant difference in the uptake by naive MDSCs (day
0 CFU; Figure 2A). Thus, we demonstrate that LILRB2 mabmediated antagonism rapidly enhances the killing of Mtb,
increasing to a 0.8-log10 decline in CFU by 3 days.
Earlier, we have shown that mab-B2 blockade of LILRB2
switches the MDSC phenotype into an M1-MФ phenotype (16).
To determine whether mab-B2 induces a similar switch, Mtbinfected MDSCs were collected on days 1 and 3 post mab-B2
treatment, and tested for the mRNA expression of CD80 and
CD206, which are markers of M1-MФs and M2-MФs,
respectively (23). In addition, we evaluated mRNA for Guanylate
binding protein 2 (GBP2), which is an IFN-g-inducible marker
associated with the control of mycobacterial infection in mice
(24–26). Mtb-infected MDSCs treated with mab-B2 showed an

to conﬁrm the presence of N-MDSCs and M-MDSCs in samples of
TB patients and compared with donors; Supplementary Figure 3
shows the t-SNE plots of immune cell composition and
Supplementary Table 1 indicates the clinical status of TB
patients and controls.

LILRB2-Speciﬁc Mab-Mediated
Antagonism of MDSCs Enhances Their
Bactericidal Function Through Nitric
Oxide and Reactive Oxygen Species
Using CD14 and CD33 bead fractionation, M-MDSCs were
puriﬁed from PBMCs of healthy donors. They were infected
for 4 h with Mtb, washed, and then treated with either mab-B2 or
its isotype followed by incubation for Mtb growth assay.
Figure 2A indicates that the Mtb CFU counts progressively
declined over 3 days, whereas their numbers remained stable in
untreated or IgG isotype-treated MDSCs. Because MDSCs were
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E
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C

D

G

F

FIGURE 2 | A monoclonal antibody to leukocyte immunoglobulin-like receptor B2 (LILRB2) enhances the killing of Mycobacterium tuberculosis (Mtb) in MDSCs through nitric
oxide. (A) CD14+/CD33+ bead-puriﬁed M-MDSCs derived from GM-CSF/IL-6 cultured PBMCs of a healthy donor were infected for 4 h with Mtb H37Rv (MOI = 1), washed,
and activated using either a monoclonal antibody to LILRB2 (mab-B2; 1 µg/ml) or its IgG isotype (1 µg/ml) or left untreated. MDSC lysates were plated at indicated time points
for Mtb CFUs on 7H11 agar (triplicate wells per point; **p < 0.007 1-way ANOVA and Tukey’s posttest; 1 of 2 similar experiments shown). (B) At indicated time points, MDSC
cell lysates in trizol were collected for qPCR for CD80, CD206, and Guanylate binding protein-2 biomarkers (1 of 2 similar experiments shown). (C) MDSCs were treated with
siRNA vs. inducible nitric oxide synthase (iNOS) or its scrambled control followed by 4 h Mtb infection (MOI = 1), washed, and activated using mab-B2 or its isotype and
incubation for 3 days before CFU counts (triplicate wells per point; **p < 0.009 1-way ANOVA; 1 of 2 similar experiments shown). (D) Replicates of panel C were incubated
with Diaminoﬂuorescein diacetate followed by a ﬂuorometric detection of soluble nitrite in medium (triplicate wells per point; *p < 0.009 t-test; 1 of 2 experiments shown).
(E) Cell lysates of panel C were tested for iNOS protein using ProteinSimple-Wes capillary electrophoresis. Expression of iNOS was normalized to b-actin. Supplementary
Figure 2 illustrates the Wes-capillary gel analysis. (F) Densitometry of proteins for panel E (*p < 0.001 t-test). (G) Relative production of reactive oxygen species (ROS) by
MDSC with and without treatment of mab-B2 following Mtb infection. ROS was detected using dihydro-dichloro-ﬂuorescein aceate and ﬂuorometry (*p < 0.001 t-test).

reduced the levels of iNOS protein (Figure 2F). We note here
that LILRB2 signals through the src-homolgy containing
phosphatases (SHP)-1 and 2 (14). Because SHP-1 mediates
negative reguation of iNOS (27), we suggest that mab-B2LILRB2 blockade suppressed SHP-1 to increase NO, essentially
switching MDSCs to an M1-MФ-like phenotype and controlling
Mtb growth.
Since MФs can also induce the killing of Mtb using ROS, we
sought to determine whether blockdade of LILRB2 induces the
ROS; ROS was marginally increased in Mtb-infected MDSC after
mab-B2 treatment (Figure 2G). Together, these data conﬁrm that
mab-B2 induces Mtb-infected MDSCs to switch into an M1-MФ
like phenotype, increasing NO and ROS and controlling the growth
of Mtb.

upregulation of CD80 and a downregulation of CD206 consistent
with an M1-MФ phenotype (Figure 2B). GBP2, a biomarker for
M1-MФs, was maintained between day 1 and day 3 after
LILRB2 blockade.
Since MФs can kill Mtb using NO, we sought to determine
whether mab-B2 induced iNOS, which, in turn, can generate NO
to boost the bactericial funciton of MDSCs. iNOS synthesis in
MDSCs was therefore blocked using siRNA vs. iNOS followed by
Mtb infection and incubation with mab-B2 or IgG isotype.
Treatment with mab-B2 reduced the Mtb viable counts
compared to IgG-treated MDSCs (Figure 2C). Moroever, mabB2-induced intracellular killing of Mtb was abrogated when
iNOS was inhibited (Figures 2C, D). Replicate cultures of
similarly treated MDSCs showed that mab-B2-enhanced NO
was conﬁrmed by the presence of nitrite in the medium detected
using a diaminonapthalene (DAN) ﬂuorescent indicator and
ﬂuorometry (19) (Figure 2D). Western blot analysis of iNOS
conﬁrmed that the barely detetable iNOS protein in Mtb-infected
MDSCs was enhanced after mab-B2 treatment (Figures 2E, F).
Speciﬁc siRNA knockdown of iNOS but not scramled siRNA
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mab-B2-induced autophagy through secretion of sapM
phosphatase, which cleaves phosphatidyl-3 inositol phosphate
(PI3P) that is associated with phagosomes preventing
autophagolysosome fusion. In this direction, we reported that a
DfbpADsapM mutant of Mtb is lysosome fusion competent (31, 32).

and SNARE-dependent phagosome–lysosome (PL) fusion or
through autophago-lysosome fusion regulated by ATGs (28, 29).
To determine whether autophagy plays a role after LILRB2
antagonism, MDSCs were subjected to siRNA knockdown of
beclin1 (ATG6) and scrambled siRNA controls. Following Mtb
infection, MDSCs were treated with mab-B2 or IgG isotype and
incubation for Mtb growth assay. Unexpectedly, siRNA-mediated
autophagy blockade of MDSCs did not reverse the Mb growth in
mab-B2-treated cells (Figure 3A). This was interesting because
mab-B2 induced an enrichment of the autophagy marker protein,
microtubule-associated light chain-3 (LC3-II) (Figures 3B, C).
During autophagolysosome fusion, the lipidated form of LC3-II is
enriched on the phagosomes of Mtb. Fluorescent immunostaining
using antibodies to LC3 also conﬁrmed that many gfpMtb
phagosomes were enriched for LC3 labeling (Figures 3D, E).
Therefore, a lack of autophagy-mediated killing of Mtb in MDSCs
was in contrast with LC3 enrichment of their phagosomes.
However, we note that Mtb phagosomes can transiently label
with LC3 even without causing the autophagic ﬂux, which
delivers them to lysosomes (30). Alternatively, Mtb may evade

LILRB2 Antagonism in MDSCs
Renders Them Bactericidal for a
Subsequent Mtb Infection
Because LILRB2 blockade led to increased killing of Mtb by MDSCs
(Figure 2A), we sought to determine whether it can also “precondition” MDSCs to prevent a subsequent Mtb infection and
growth. First, CD33+ MDSCs were puriﬁed using FACsort from
donor PBMCs and treated with mab-B2 and LILRB3-speciﬁc mabB3, followed 1 day later by infection with Mtb and growth assay
over 7 days. Figure 4A indicates that mab-B2 and mab-B3
(antagonistic for LILRB3) treatment signﬁcantly reduced the
uptake of Mtb by MDSCs on day 1. However, both mabs still
activated MDSCs to kill Mtb over 7 days. Next, CD14+CD33+
MDSCs bead puriﬁed from PBMCs cultured in GM-CSF/IL-6 (used

A
C
B

D

E

FIGURE 3 | LILRB2 antagonism effects on the bactericidal function of the MDSCs are independent of autophagy. (A) CD14+/CD33+ bead-puriﬁed M-MDSCs derived
from GM-CSF/IL-6 cultured PBMCs from donors were subjected to autophagy blockade using siRNA vs. beclin1 (ATG6) or its scrambled control, followed by infection
with Mtb H37Rv (MOI = 1), washed, and incubated after activation with mab-B2 or isotype. MDSC lysates were plated on day 3 for Mtb CFUs on 7H11 agar (triplicate
wells per point; p < 0.008, 1-way ANOVA and Tukey’s posttest; 1 of 2 similar experiments shown). (B) Lysates of cells from panel A were collected at 18 h and analyzed
using Western blot for the autophagy marker, microtublue-associated light chain-3 (LC3). Lipidation is indicated by LC3-II. (C) Densitometry of cells from panel B indicates
the expression of LC3 normalized to GAPDH. (*p < 0.01 t-test). (D) M-MDSCs were infected with gfpMtb (4 h MOI = 1) followed by ﬁxation in 3.7% paraformadehyde
and staining using mab to LC3 followed by Alexaﬂuor590 anti-IgG conjugate. Images were acquired using an N90 Nikon scope with Metaview deconvolution software.
(E) Data show quantitation of gfpMtb phagosomes colocalizing with mab-LC3 staining (*p < 0.05, **p < 0.005, t-test; 1 of 2 similar experiments shown).
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FIGURE 4 | Prior treatment of MDSCs with monoclonal antibodies to leukocyte immunoglobulin-like receptors B2 and B3 (LILRB2/3) enhances their bactericidal
function against Mtb. (A, B) CD33+ ﬂow sorted MDSCs from donor PBMCs (A) or CD14+/CD33+ bead-puriﬁed M-MDSCs derived from GM-CSF/IL-6 cultured
PBMCs from donors (B) were activated or not with monoclonal antagonist antibodies to LILRB2 (mab-B2) or LILRB3 (mab-B3) followed by infection with Mtb H37Rv
(MOI = 1) and incubation over time. Lysates were plated at indicated time points for Mtb CFUs on 7H11 agar (*, **p < 0.007 1-way ANOVA and Tukey’s posttest; 1
of 2 similar experiments shown).

for Figures 1–4) were treated using mab-B2/3 followed by Mtb
infection and CFU assay. Similar to MDSCs directly puriﬁed from
blood (Figure 4A), culture-grown MDSCs also enhanced the killing
Mtb upon LILRB2/3 blockade despite the difference in uptake of
Mtb on day 1 (Figure 4B).

SHP-1 and SHP-2, respectively, showed a rapid and synergistic
reduction of Mtb burden in MDSCs. Synergy suggests that
LILRB2 may not solely go through the SHP1/2 pathway;
alternatively, other LILRB members may signal through
SHP1/2. MDSCs treated with mab-B2 showed 0.6 log10
reduction of Mtb CFU compared to IgG control by day 3,
whereas we found ~1.8 log reduction of Mtb CFUs in the mabB2–SHP1/2 inhibitor combination (Figure 6A). This
observation correlated with an increased phosphorylation of
ERK1/2 and p38 MAPK activation compared to MDSC treated
with IgG and SHP-1 and SHP-2 inhibitors (Figure 6B). Thus,
LILRB2 antagonism through mab in combination with the
disruption of SHP1/2 enhances ERK1/2, p38 MAPK, and the
robust killing of intracellular Mtb.

LILRB2 Antagonism Activates ERK1/2, p38
MAPK, and NF-kB in Mtb-Infected MDSCs
Increasing Inﬂammatory Cytokines
Inﬂammatory phenotypes of M1-MФs are associated with NFkB/STAT1 activation (33). Because LILRB2 antagonism led to an
M1-type switch in MDSCs (Figure 2B), we evaluated
downstream signaling mechanisms after mab treatment in
Mtb-infected MDSCs. LILRB2 mab-treated MDSCs showed
in crease d E RK 1/2, p38 MAPK, and N F-k B/STAT1
phosphorylation in Mtb-infected MDSCs after Mtb infection
compared to IgG controls (Figure 5A). We reported earlier that
LILRB receptors constitutively recruit and activate SHP-1 (SH2
domain-containing protein tyrosine phosphatase-2) in
macrophages (16). Consistent with this observation, LILRB2associated SHP-1 phosphorylation was reduced in mab-B2
treated Mtb-infected MDSCs compared to IgG controls
(Figure 5B). These data suggest that LILRB2 antagonism
disrupts SHP-1 and increases downstream inﬂammatory
signaling cascades through phosphorylated ERK1/2, p38
MAPK pathways, and NF-kB and STAT1 transcription factors.

LILRB2 Antagonism Enhances IRF
Transcription Factors and
Pro-Inﬂammatory Cytokine Secretion by
Mtb-Infected MDSCs
A downstream mechanism of SHP2 is its inhibition of
transcriptional activity of IRF-1 and IRF-8 at the IFN-b
promoter. Whereas IRF1, IRF5, and IRF8 promote M1-type
polarization of macrophages, IRF3 and IRF4 promote M2
differentiation (34). LILRB2 treatment with mab-B2
upregulated IRF3 and IRF5 compared to IgG controls in Mtbinfected MDSCs (Figure 7A), conﬁrming a switch of MDSCs
into the M1 phenotype. To determine whether IRF changes are
associated with cytokine secretion, MDSCs were treated with
mab-B2, SHP1/2 inhibitors (TPI-1 and IACS), or their
combination followed by cytokine assay. Treatment with mabB2 alone was enough to increase pro-inﬂammatory TNF-a,
whereas a combination of mab-B2 blockade and SHP1/2
inhibitor led to elevated TNF-a, IL-6, and IL-1b (Figure 7B).
In contrast, mab-B2 or SHP1/2 inhibitors decreased the levels of
anti-inﬂammatory IL-10. We recall here that both IL-1b and
TNF-a are macrophage-activating cytokines (35, 36).

LILRB2 Antagonism and SHP1/2
Phosphatase Inhibition Synergize
to Kill Mtb in MDSCs
Because LILRB2 antagonism in Mtb-infected MDSCs reduced
SHP-1 phosphorylation (Figure 5B), we pharmacologically
blocked SHP1/2 to boost mab-B2-mediated antagonism. To
demonstrate synergy, Mtb-infected MDSCs were plated for
CFUs by 18 h post treatment. Remarkably, mab-B2 in
combination with TPI-1 and IACS, which are inhibitors of
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FIGURE 5 | LILRB2 antagonism drives the STAT1/NF-kB inﬂammatory pathway in Mtb-infected MDSCs. CD14+/CD33+ bead-puriﬁed M-MDSCs derived from GM-CSF/
IL-6 cultured PBMCs from donors were infected for 4 h with Mtb H37Rv (MOI = 1), washed, and activated using either a monoclonal antibody to LILRB2 (mab-B2) or its
IgG isotype. MDSC lysates were collected at 18 h post infection in RIPA buffer for Western blots and densitometry. (A) Immunoblot of phosphorylated STAT1, p38 MAPK,
NF-kB, and ERK1/2 in MDSCs treated as above. Densitometry shown to the right (*p < 0.02, unpaired t-test). (B) Immunoblot of phosphorylated SHP1 in MDSCs treated
as above (*p < 0.02 unpaired t-test) (SHP2 was not affected; not shown; 1 of 2 similar experiments shown).

MDSCs express myeloid activating and inhibitory receptors,
including the LILR-A/B family (14). The paired
immunoglobulin-like receptor B (PIR-B) is the only mouse
receptor ortholog of the human LILRB family. Previously, we
demonstrated that reprogramming of the MDSCs using LILRB2
blockade led to increased anticancer responses and such cells
expressed an M1-like gene expression (16). Since M1-MФs can
reduce the Mtb growth better than M2-MФs (2), we
hypothesized that LILRB2 blockade can induce an M1-like
switch in MDSCs facilitating a better control of Mtb growth.
First, we conﬁrmed that MDSCs do occur in patients with
tuberculosis, although the PBMCs seemed to contain a higher
number of G-MDSCs (Figure 1). We continued our studies using
M-MDSCs because macrophages dominate in the TB granulomas
of lungs, and their sequestration in granulomas may render them

DISCUSSION
MDSCs are a distinct class of suppressor cells that mediate
immune regulation during chronic inﬂammation and
infectious diseases (9, 10). In the context of tuberculosis, the
lung granulomas seem to contain MDSCs, presumably of both
monocytic and granulocytic origin (7) (10). In vitro cultures of
MDSCs allow increased growth of Mtb, even though they seem
to secrete more inﬂammatory cytokines (37). Because MDSCsecreted cytokines can affect the function of both MФs and T
cells within the micro-environment of granulomas, they can be
targets for immunotherapy (38). In this study, we have
investigated a novel LILRB2/3 receptor-dependent pathway in
MDSCs to enhance their ability to kill Mtb and prevent
exacerbation of TB.
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FIGURE 6 | Mab-B2 antagonism of LILRB2 and pharmacological inhibition of SHP1/2 synergistically boost killing of Mtb in MDSCs. CD14+/CD33+ bead-puriﬁed MMDSCs derived from GM-CSF/IL-6 cultured PBMCs from donors were infected for 4 h with Mtb H37Rv (MOI = 1), washed, and activated using either a monoclonal
antibody to LILRB2 (mab-B2) or its IgG isotype with or without added SHP-1 and SHP-2 inhibitors (1 µg/ml each per 10*6 cells). (A) MDSC lysates collected 18 h
after infection were plated for Mtb CFUs on 7H11 agar (**p < 0.002 by 1- way ANOVA with Tukey’s posttest; 1 of 2 similar experiments shown).(B) Lysates collected
from replicate cultures of MDSCs were analyzed using Wes simple Western blot for phosphorylated ERK1/2 and p-38 kinases, and densitometry is shown to the
right (*p < 0.02, unpaired t-test).

side effect of adaptive immune cell suppression may be beneﬁcial
depending on the stage of TB; mabs may reduce pathologic
inﬂammation and prevent lung damage during chronic or acute
TB. This concept needs to be investigated using animal models of
TB. We recall here that LILRB2 is also expressed by many other
innate cells, including mesenchymal stem cells, neutrophils, and
MФs, all of which can harbor Mtb (43, 44). The therapeutic effects
of LILRB2/3 mabs on these cell populations need to be determined.
Of note, we tested LILRB2 blockade both before and after Mtb
infection because patients with TB and MDR-TB can be targeted
using mab-B2 immunotherapy, and in addition, people at risk of
TB can perhaps be given mab-B2 injections. We found that prior
blockade of LIRB2/3 using mabs led to a moderate decrease in the
uptake of Mtb organisms, which is consistent with the report that
LILRB3 may affect FcR-mediated phagocytosis in macrophages
(45). This line of research requires additional inevstigation. We
also noted that isotype IgG by itself caused a moderate decline in
the CFU counts of Mtb when added prior to but not after Mtb
infection (Figure 2A vs. Figures 4A, B). This is likely because,
when mab is added ﬁrst, it may suppress Fc-R-dependent uptake
of Mtb, a known non-opsonic pathway for mycobacterial uptake
(46, 47). Nonetheless, mab-B2 induced a robust deline in Mtb
viability compared to IgG treatment (Figures 4A, B).

less detectable in peripheral blood. Using in vitro cultures of
PBMC-derived M-MDSCs, we found that LILRB2 blockade led
to an increased killing of Mtb (Figure 2A). Importantly, mab-B2treated MDSCs upregulated CD80, a marker of M1-MФs, and
downregulated the CD206 biomarker of M2-MФs (Figure 2B).
Intriguingly, increased bactericidal function of LILRB2antagonized MDSCs was dependent on NO, and such cells also
had increased ROS (Figure 3). On the other hand, blockade of
autophagy had no effect on the growth of Mtb in mab-B2-treated
MDSCs, although Mtb phagosomes still showed an increase in LC3
labeling (Figure 4). We recall here that Mtb phagosomes can
acquire a transient labeling of LC3, but can also actively evade
autophagolysosomal fusion in macrophages (39).
MDSCs are known to produce elevated levels of NO through
iNOS (40), and interestingly, LILRB2 mab treatment
(Figures 2C–F) enhanced NO response, which supports the
concept of mab therapy which can perhaps clear MDSCs of Mtb
organisms. However, we note that increased expression of NO and
IDO by MDSCs and other cells may also suppress the T cellmediated adaptive immune responses during TB (41, 42).
Therefore, mab therapy of MDSCs can enhance bactericidal
function but may also interfere with the adaptive arm of T cellmediated anti-TB immunity. It is also possible that the unwanted
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FIGURE 7 | LILRB2 antagonism enhances inﬂammatory cytokines in Mtb-infected MDSCs. CD14+/CD33+ bead-puriﬁed M-MDSCs derived from GM-CSF/IL-6
cultured PBMCs from donors were infected for 4 h with Mtb H37Rv (MOI = 1), washed, and activated using either a monoclonal antibody to LILRB2 (mab-B2; 1 µg/
ml/10*6 cells) or its IgG isotype (1 µg/ml/10*6 cells) and SHP 1/2 inhibitors (1 µg/ml of each per 10*6 cells). Cells were lysed in trizol for qPCR and supernatants
were tested for cytokines. (A) qPCR mRNA quantitation after mab-B2 or IgG treatment of Mtb-infected MDSCs at 18 h post infection (*p < 0.02 **, unpaired t-test).
(B) Supernantants were collected at 18 h post infection and cytokines were assayed using sandwich ELISA (*p < 0.01 **, unpaired t-test).

SHP1/2 may have a synergistic effect on MDSCs. Indeed, SHP
inhibitors are known to boost anticancer agents affecting MDSCs
(51). We found a strong synergy between mab-B2 and a
combination of SHP1/2 inhibitors (Figure 6A) that was
associated with enhanced phosphorylation of p38 MAPK and
ERK1/2 (Figure 6B). These data suggest that mab-B2 and SHP1/
2 blockade could pave the way for a more effective
immunotherapy for drug-sensitive and MDR-Mtb organisms.
Since MDSCs can affect bystander immune cells through
cytokine secretion, we analyzed cytokine proﬁles after LILRB2
antagonism. A combination of mab-B2 and SHP1/2 blockade
enhanced Th1 (TNF-a, IL-6, and IL-1b) cytokine secretion and
reduced 1L-10 (Figure 7). Because these cytokines perform antituberculosis function, we conclude that LILRB2 is an attractive
MDSC-related therapeutic target for tuberculosis control.
Despite the intriguing therapeutic effects of mabs to LIRB2/3, we
note the following caveats. The number of MDSCs inﬁltrating to
lungs could be limited and other myeloid cells that may or may not
express LILRB2 like mesenchymal stem cells, dendritic cells,
neutrophils, and M2-M Фs may also contribute to

Our earlier studies show that LILRB2 blockade suppresses the
SHP1/2 phosphorylation, inducing an M1 phenotype through
enhanced ERK1/2 and p38 MAPK phosphorylation and
downstream activation of NF-kB and STAT-1 (16). Consistent
with these ﬁndings, mab-B2 antagonism of LILRB2 in Mtbinfected MDSCs also led to enhanced STAT1, p38 MAPK, NFkB, and ERK1/2 phosphorylation (Figure 5A), correlating with
reduced SHP1/2 phosphorylation (Figure 5B). The increased
STAT1 phosphorylation after mab-B2 blockade in MDSCs
assumes importance because, during progressive Mtb infection
of mouse macrophages, the levels of unphosphorylated STAT1
increases facilitating pathogen survival (48). Likewise, virulent
Mtb shows immune evasion reducing ERK1/2 (49) and p38
MAPK phosphorylation (50), both of which increase Mtb
survival in macrophages. We conclude that mab-B2 exerts its
therapeutic effect through an enhanced phosphorylation of
pivotal kinases and transcription factors in MDSCs.
Finally, we noted that activation of SHP1/2 is a key event
downstream of LILRB2 and hypothesized that a combination of
antagonism through mab-B2 and pharmacological blockade of
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immunosuppressive activity during TB (52) (53). Whether LILRB2/
3 are expressed by the latter and amenable for mab therapy remains
to be elucidated using ex vivo models and mice. Nonetheless, we
anticipate that LILRB2/3-dependent signaling mechanisms are
attractive therapeutic targets for the control of TB.
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